Akthelia was founded by four eminent professors from the Karolinska Institute in Sweden and the University of Iceland.
The company is focused on the discovery and development of therapeutics that enhance and deploy the body's own innate defense mechanisms to combat debilitating diseases.
Unlocking healthier futures with epithelial reprogramming
Today, Akthelia is an exciting preclinical-stage biopharma company committed to developing innovative therapies that improve the lives of patients worldwide.
Our mission is to discover and develop new treatments that enhance and deploy the body's own innate microbial defense mechanisms to combat debilitating diseases.
We believe that our approach has the potential to revolutionize the way that we treat a wide range of diseases, including cancer, infection, and autoimmune disorders.
Akthelia's foundation was based on more than a decade of ground-breaking research into human host defense peptides and the mechanisms of barrier dysfunction by our scientific founders at the University of Iceland and the Karolinska Institute.
Emerging from early work on short chain fatty acid effects on epithelia, our first IP came from human cell-based reporter assays to select for the amplification of host immunity in epithelial surfaces. Aroylated phenylenediamines (APDs) were identified as potential drug candidates and one of our core patents was filed around the application of this class of compound.
We have a capital efficient core team complemented by an wider group of retained advisors, consultants and key opinion leader clinicians, providing expertise across the spectrum of scientific, medical and therapeutic development expertise.
OUR EQUAL OPPORTUNITIES PROMISE
We are committed to building a team that represents a variety of backgrounds, perspectives, and skills. The more inclusive we are, the better our work will be.
At Akthelia Pharmaceuticals, we are committed to fostering, cultivating, and preserving a culture of diversity, equity, and inclusion. Our human capital is our most valuable asset – the collective sum of the individual differences, life experiences, knowledge, innovation, self-expression, and talent that our employees invest in their work represents a significant part of not only our culture but our reputation and company’s achievement as well.
Equal Employment Opportunity
We provide equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, sex, national origin, age, disability, or genetics. Akthelia Pharmaceuticals complies with applicable international, federal and local laws governing nondiscrimination in employment in every location in which the company has facilities.
Respectful Work Environment
We believe that the wide array of perspectives that results from such diversity promotes innovation and business success. Managing diversity makes us more creative, flexible, productive, and competitive.
Recruitment and Career Development
Recruitment, hiring, training, and promotion of persons in all job titles shall be based on qualifications and job performance. All employees have the right to be treated with dignity and respect.
Accessibility and Accommodations
We are committed to making our application process and workplace accessible for individuals with disabilities. Akthelia Pharmaceuticals will provide reasonable accommodations to individuals with disabilities who need assistance applying for a job or to employees who need assistance with their job.
We recognize that the responsibility for diversity and inclusion lies with all at the workplace. We are committed to continuous improvement and periodic review of our diversity practices and policy.